The fever could boil over if the FDA loosens restrictions on peptide drugs that agency scientists say remain insufficiently studied. Karthik Achari, clinician and founder of PepMD, who spoke at the recent FDA meeting, told Newsweek the core problem is structural. Safety Data Tells a Different Story 0 Share Newsweek is a Trust Project member See more of our trusted coverage when you search. The fever could boil over if the FDA loosens restrictions on peptide drugs that agency scientists say remain insufficiently studied. Karthik Achari, clinician and founder of PepMD, who spoke at the recent FDA meeting, told Newsweek the core problem is structural.